Gentronix, Part of Scantox Group

Gentronix Limited is a biotechnology startup based in the United Kingdom, specializing in delivering predictive toxicology products and services to global chemical sectors. With a focus on genetic toxicology and skin sensitization, the company works with organizations from early screening through to regulatory safety assessment, providing innovative solutions for identifying genotoxic hazards and assessing chemical safety. Established in 1999, Gentronix has been a key player in the predictive toxicology space for over 20 years, assisting clients in optimizing their development programs. The company offers a comprehensive portfolio of screening and regulatory genotoxicity products and services, as well as the assessment of skin sensitization potential. Gentronix recently received a £700.00K Venture Round investment on 15 November 2021, with Mercia Fund Managers participating as the investor. This investment highlights the recognition and confidence in the company's expertise in the field of predictive toxicology. With its established track record and focus on innovation, Gentronix is well-positioned to further solidify its standing as a leader in the predictive toxicology industry.